Golf, I wouldn't disagree with your summary but I'm not sure that current management has the requisite skills to get us there. They have thus far not been able to run their business or share their story in a way that even comes close to attracting the investment community at large. 

One nice thing about the Constellation sale is that their lead candidate is a BET inhibitor in ph 3 (according to their pipeline chart). That should draw some positive attention to the BET inhibition space.  $1.7B USD will attract some attention.  Pretty sad that Resverlogix has a BET inhibitor with blockbuster potential and BTD yet management can only muster up a market cap that is about 10-12% of Constellation's. As my Dad would say, come on Don, get off your a$$ and get something done!